Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Cromer

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
Nature Medicine|May 18, 2021
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionDavid S Khoury, Deborah Cromer, Arnold Reynaldi, et al.
Nature Reviews. Immunology|April 28, 2022
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?Stephen J Kent, David S Khoury, Arnold Reynaldi, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2017
Host-mediated impairment of parasite maturation during blood-stage <i>Plasmodium</i> infectionDavid S Khoury, Deborah Cromer, Jasmin Akter, et al.
Plos Pathogens|July 3, 2015
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV RemissionMykola Pinkevych, Deborah Cromer, Martin Tolstrup, et al.
Pathology|July 18, 2024
Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemiaMaxine Revoltar, Riana van der Linde, Deborah Cromer, et al.
Plos Pathogens|August 26, 2016
Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV RemissionMykola Pinkevych, Deborah Cromer, Martin Tolstrup, et al.
Elife|August 14, 2020
Early analysis of the Australian COVID-19 epidemicDavid J Price, Freya M Shearer, Michael T Meehan, et al.
Journal of Virology|February 18, 2026
Dissecting the steps in early simian immunodeficiency virus dissemination following mucosal and intravenous infection of rhesus macaquesSteffen S Docken, Agatha Macairan, Timothy E Schlub, et al.
Nature Communications|July 28, 2023
Monoclonal antibody levels and protection from COVID-19Eva Stadler, Martin T Burgess, Timothy E Schlub, et al.
Malaria Journal|February 17, 2022
Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in miceArya SheelaNair, Aleksandra S Romanczuk, Rosemary A Aogo, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Nature Medicine|May 18, 2021
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionDavid S Khoury, Deborah Cromer, Arnold Reynaldi, et al.
Nature Reviews. Immunology|April 28, 2022
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?Stephen J Kent, David S Khoury, Arnold Reynaldi, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2017
Host-mediated impairment of parasite maturation during blood-stage <i>Plasmodium</i> infectionDavid S Khoury, Deborah Cromer, Jasmin Akter, et al.
Plos Pathogens|July 3, 2015
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV RemissionMykola Pinkevych, Deborah Cromer, Martin Tolstrup, et al.
Pathology|July 18, 2024
Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemiaMaxine Revoltar, Riana van der Linde, Deborah Cromer, et al.
Plos Pathogens|August 26, 2016
Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV RemissionMykola Pinkevych, Deborah Cromer, Martin Tolstrup, et al.
Elife|August 14, 2020
Early analysis of the Australian COVID-19 epidemicDavid J Price, Freya M Shearer, Michael T Meehan, et al.
Journal of Virology|February 18, 2026
Dissecting the steps in early simian immunodeficiency virus dissemination following mucosal and intravenous infection of rhesus macaquesSteffen S Docken, Agatha Macairan, Timothy E Schlub, et al.
Nature Communications|July 28, 2023
Monoclonal antibody levels and protection from COVID-19Eva Stadler, Martin T Burgess, Timothy E Schlub, et al.
Malaria Journal|February 17, 2022
Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in miceArya SheelaNair, Aleksandra S Romanczuk, Rosemary A Aogo, et al.
Pageof 9